An open-label, phase 2 study to evaluate the safety and efficacy of glufosfamide in the treatment of patients with recurrent sensitive small cell lung carcinoma

Trial Profile

An open-label, phase 2 study to evaluate the safety and efficacy of glufosfamide in the treatment of patients with recurrent sensitive small cell lung carcinoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2015

At a glance

  • Drugs Glufosfamide (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Threshold Pharmaceuticals
  • Most Recent Events

    • 05 Dec 2007 Status changed from in progress to discontinued.
    • 15 Oct 2007 Enrolment into the trial has been stopped due to a low clinical response rate in the initial 21 patients. Currently enrolled patients will be given the option to continue in the trial.
    • 11 Oct 2007 Status change from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top